Phosphoinositide 3-kinase in Health and Disease
Rommel, Christian
Vanhaesebroeck, Bart
Vogt, Peter K.
192,39 €(IVA inc.)
From humble beginnings over 25 years ago as a lipid kinase activity associated with certain oncoproteins, PI3K (phosphoinositide 3-kinase) has been catapulted to the forefront of drug development in cancer, immunity and thrombosis, with the first clinical trials of PI3K pathway inhibitors now in progress. Here we give a brief overview of some key discoveries in the PI3K area and their impact, and include thoughts on the current state of the field, and where it could go from here
- ISBN: 978-3-642-26522-8
- Editorial: Springer
- Encuadernacion: Rústica
- Fecha Publicación: 07/11/2012
- Nº Volúmenes: 1
- Idioma: Inglés